成都闻泰医药科技

Wentai Pharmaceutical is a clinical-stage biotechnology company headquartered in Chengdu, China, focused on developing innovative small molecule drugs for metabolic and inflammatory diseases. The company utilizes a proprietary structure-based drug design platform to target complex biological pathways, with a particular emphasis on thyroid hormone receptors and G protein-coupled receptors (GPCRs). Its lead program, WNT0508, is a potent and highly selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 2 clinical development for metabolic dysfunction-associated steatohepatitis (MASH). Beyond liver disease, Wentai is advancing a pipeline of oral candidates targeting obesity and type 2 diabetes, including small molecule GLP-1 receptor agonists. The company is backed by prominent venture capital firms and operates out of the Chengdu Tianfu International Bio-town. Wentai aims to address the global burden of chronic metabolic conditions through precision-engineered chemical entities.